{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "MUC1",
      "imaging",
      "immunotherapy",
      "radiopharmaceuticals"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33821638",
  "DateCompleted": {
    "Year": "2021",
    "Month": "11",
    "Day": "22"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "11",
    "Day": "22"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "04",
        "Day": "06"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1021/acs.molpharmaceut.0c01249"
    ],
    "Journal": {
      "ISSN": "1543-8392",
      "JournalIssue": {
        "Volume": "18",
        "Issue": "5",
        "PubDate": {
          "Year": "2021",
          "Month": "May",
          "Day": "03"
        }
      },
      "Title": "Molecular pharmaceutics",
      "ISOAbbreviation": "Mol Pharm"
    },
    "ArticleTitle": "MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy.",
    "Pagination": {
      "StartPage": "1842",
      "EndPage": "1861",
      "MedlinePgn": "1842-1861"
    },
    "Abstract": {
      "AbstractText": [
        "Mucin 1 (MUC1) is a large, transmembrane mucin glycoprotein overexpressed in most adenocarcinomas and plays an important role in tumor progression. Regarding its cellular distribution, biochemical features, and function, tumor-related MUC1 varies from the MUC1 expressed in normal cells. Therefore, targeting MUC1 for cancer immunotherapy and imaging can exploit the difference between cancerous and normal cells. Radiopharmaceuticals have a potential use as carriers for the delivery of radionuclides to tumors for a diagnostic imaging and radiotherapy. Several radiolabeled targeting molecules like peptides, antibodies, and aptamers have been efficiently demonstrated in detecting and treating cancer by targeting MUC1. This review provides a brief overview of the current status of developments and applications of MUC1-targeted radiopharmaceuticals in cancer imaging and therapy."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Research Center of oils and fats, Food and Drug Administration, Kermanshah University of Medical sciences, Kermanshah, Iran."
          }
        ],
        "LastName": "Maleki",
        "ForeName": "Fariba",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran."
          }
        ],
        "LastName": "Rezazadeh",
        "ForeName": "Farzaneh",
        "Initials": "F"
      },
      {
        "Identifier": [
          "0000-0002-4776-5794"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Research Center of oils and fats, Food and Drug Administration, Kermanshah University of Medical sciences, Kermanshah, Iran."
          }
        ],
        "LastName": "Varmira",
        "ForeName": "Kambiz",
        "Initials": "K"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Mol Pharm",
    "NlmUniqueID": "101197791",
    "ISSNLinking": "1543-8384"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antigens, Neoplasm"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Drug Carriers"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "MUC1 protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Mucin-1"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Radiopharmaceuticals"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "diagnostic imaging",
        "immunology",
        "therapy"
      ],
      "DescriptorName": "Adenocarcinoma"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Antigens, Neoplasm"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cell Line, Tumor"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Models, Animal"
    },
    {
      "QualifierName": [
        "chemistry"
      ],
      "DescriptorName": "Drug Carriers"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Immunotherapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mice"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Molecular Imaging"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Mucin-1"
    },
    {
      "QualifierName": [
        "diagnostic imaging",
        "immunology",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "chemistry",
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Radiopharmaceuticals"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Xenograft Model Antitumor Assays"
    }
  ]
}